clinical trial · NCT03121586
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
SchizophreniaPimavanserin
brief summary
To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia
started
Jan 1, 2017
primary completion
Apr 30, 2024
completion
May 30, 2024
last updated
Aug 24, 2025
official title
A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol